



Vitamin D levels and cancer incidence in 217,244 individuals from primary health care in Denmark

Vojdeman, Fie Juhl; Madsen, Christian Medom; Frederiksen, Kirsten; Durup, Darshana; Olsen, Anja; Hansen, Louise; Heegaard, Anne Marie; Lind, Bent; Tjønneland, Anne; Jørgensen, Henrik Løvendahl; Schwarz, Peter

Published in:
International Journal of Cancer

DOI:
[10.1002/ijc.32105](https://doi.org/10.1002/ijc.32105)

Publication date:
2019

Document version
Publisher's PDF, also known as Version of record

Document license:
[CC BY](#)

Citation for published version (APA):
Vojdeman, F. J., Madsen, C. M., Frederiksen, K., Durup, D., Olsen, A., Hansen, L., Heegaard, A. M., Lind, B., Tjønneland, A., Jørgensen, H. L., & Schwarz, P. (2019). Vitamin D levels and cancer incidence in 217,244 individuals from primary health care in Denmark. *International Journal of Cancer*, 145(2), 338-346.
<https://doi.org/10.1002/ijc.32105>

6:43 PM DEC 01, 2022

THE MOMENT YOUR GUT INSTINCT
WAS BACKED BY SCIENTIFIC
RESULTS_



THE DIFFERENCE OF BREAKTHROUGH MOMENTS

WITH COMPLETE SOLUTIONS FOR GROUNDBREAKING DISCOVERIES FROM A TRUSTED PARTNER.

Your next breakthrough could be closer than you imagine, especially with the right resources to help you advance your research. At BD, we are dedicated to helping you get the data you need, when, where and how you need it. Our integrated solutions in instrumentation, software and reagents are optimized to work together to bring you closer to your next breakthrough moment. And you can depend on us for world-class training, service and support to help you get the most from the results your research depends on. Discover a range of optimized solutions that open endless possibilities for your future research. **Discover the new BD.**

Learn how you can advance your research >



Vitamin D levels and cancer incidence in 217,244 individuals from Primary Health Care in Denmark

Fie Juhl Vojdeman¹, Christian Medom Madsen², Kirsten Frederiksen³, Darshana Durup⁴, Anja Olsen³, Louise Hansen³, Anne-Marie Heegaard^{4,5}, Bent Lind⁶, Anne Tjønneland^{3,5}, Henrik Løvendahl Jørgensen^{5,6} and Peter Schwarz^{5,7}

¹Department of Clinical Biochemistry, Bispebjerg Frederiksberg Hospital, Copenhagen, Denmark

²Department of Clinical Biochemistry, Herlev & Gentofte Hospital, Copenhagen University Hospital, Herlev, Denmark

³Danish Cancer Society Research Center, Copenhagen, Denmark

⁴Department of Drug Design and Pharmacology, University of Copenhagen, Copenhagen, Denmark

⁵Faculty of Health Sciences, Copenhagen University, Copenhagen

⁶Department of Clinical Biochemistry, Copenhagen University Hospital Hvidovre, Hvidovre, Denmark

⁷Department of Endocrinology, Rigshospitalet, Copenhagen, Denmark

Vitamin D has been linked to cancer development in both pre-clinical and epidemiological studies. Our study examines the association between serum levels of vitamin D and cancer incidence in the Capital Region of Denmark. Individuals who had vitamin D analyzed at The Copenhagen General Practitioners Laboratory between April 2004 and January 2010 were linked to Danish registries with end of follow-up date at Dec 31st 2014, excluding individuals with pre-existing cancer. Cox regression models adjusted for age in one-year intervals, sex, month of sampling, and Charlson Comorbidity Index were applied. The study population of 217,244 individuals had a median vitamin D level of 46 nmol/L (IQR 27–67 nmol/L). Non-melanoma skin cancer was the most frequent form of cancer, followed by breast-, lung-, and prostate cancers. No associations were found between increments of 10 nmol/L vitamin D and incidence of breast, colorectal, urinary, ovary or corpus uteri cancer. However, higher levels of vitamin D were associated with higher incidence of non-melanoma (HR 1.09 [1.09–1.1]) and melanoma skin cancer (HR 1.1 [1.08–1.13]) as well as prostate (HR 1.05 [1.03–1.07]) and hematological cancers (HR 1.03 [1.01–1.06]), but with lower incidence of lung cancer (HR 0.95 [0.93–0.97]). In our study, vitamin D levels are not associated with the incidence of several major cancer types, but higher levels are significantly associated with a higher incidence of skin, prostate, and hematological cancers as well as a lower incidence of lung cancer. These results do not support an overall protective effect against cancer by vitamin D.

Introduction

25-hydroxy vitamin D (vitamin D) is a precursor for the steroid hormone calcitriol that besides having a central role in calcium homeostasis, has shown antineoplastic effects in cellular and animal studies¹. In humans, exposure of the skin to sunlight largely determines the level of circulating vitamin D with a smaller contribution from dietary intake. In the past years, several epidemiological studies and meta-analyses have examined the association between vitamin D and cancer reporting inconsistent results². The incidence of some cancer types such as colorectal cancer has generally shown inverse associations with vitamin D³ while for other cancer types such as prostate cancer, positive associations have been seen⁴.

Besides the role in calcium homeostasis, one of the biological functions of vitamin D is involvement in immune modulation. The active metabolite calcitriol has immune regulatory effects, mimicking what is seen in the immune regulatory environment in cancer⁵. Furthermore, calcitriol can also modulate the effect of known external carcinogenic substances in some cancers, e.g. by counteracting the effects of tobacco smoking on bronchial epithelium⁶. However, the effects of calcitriol might be dependent on the physiological concentration and has a biphasic effect on cancer cell growth *in vitro*⁷.

The Copenhagen General Practitioners Laboratory serviced general practitioners from the Greater Copenhagen area with approximately 1.1 million inhabitants (first quarter of 2010).

Key words: vitamin D levels, cancer incidence, primary health care

Abbreviations: CI: confidence interval; HR: Hazard ratio; IQR: Interquartile range; vitamin D: 25-hydroxy vitamin D

Additional Supporting Information may be found in the online version of this article.

Grant sponsor: Else and Mogens Wedell-Wedellsborgs Foundation; **Grant sponsor:** Lilly and Herbert Hansen Foundation

DOI: 10.1002/ijc.32105

History: Received 24 Sep 2018; ; Accepted 19 Dec 2018; Online 7 Jan 2019

Correspondence to: Fie Juhl Vojdeman, MD, PhD, Department of Clinical Biochemistry, Bispebjerg Frederiksberg Hospital, Copenhagen, Denmark, Tel.: +45-61-13-44-73, Fax: +45-38-63-98-20, E-mail: fie.juhl.vojdeman@regionh.dk

What's new?

In recent years, interest in the role of vitamin D in health has increased, and more blood tests have included vitamin D analysis. Taking advantage of these data, the authors here investigated the link between vitamin D and cancer incidence in a large Danish cohort. They found no association between circulating vitamin D and most cancers they studied. Higher levels of vitamin D did correlate with reduced risk of lung cancer, they found, and also with increased risk of skin cancers, prostate cancer, non-Hodgkin's lymphoma, and hematologic cancers.

A database (CopD) included measurements of vitamin D from this laboratory in the period from 2004 to 2010. A reverse J-shaped association between serum levels of vitamin D and all-cause mortality has been reported based on the CopD database indicating an upper beneficial limit of vitamin D⁸. This finding was corroborated by an analysis of the Third National Health and Nutrition Examination Survey, NHANES III⁹. In Denmark, like in other Western countries, awareness of the role of vitamin D in general health has increased in recent years, and a large part of the Danish population takes dietary vitamin D supplements on a regular basis¹⁰. In the period 2004 to 2010, the amount of vitamin D analyses performed at the Copenhagen General Practitioners Laboratory grew exponentially, and 14% of all requests for blood sampling included a vitamin D analysis⁸. Thus, almost one quarter of the inhabitants had their blood analyzed for vitamin D, suggesting a broad indication for vitamin D analysis. Therefore, the CopD database provides a unique opportunity to assess associations between vitamin D levels and disease outcomes in a regional population. The aim of the present study was to test the hypothesis that the level of vitamin D could be associated with both a lower and a higher incidence of cancer, depending on the type of cancer examined.

Materials and Methods**Study population**

The CopD database included measurements of vitamin D levels extracted from The Copenhagen General Practitioners Laboratory⁸. The laboratory served all general practitioners in the Copenhagen Municipality and the former Copenhagen County in Denmark. The population of the Copenhagen area was predominantly of Danish descent (83%) or non-Danish European descent (9%) in 2008 as defined by Statistics Denmark (Statistics Denmark <http://www.statbank.dk/10021>, accessed May 2018).

Our study population comprised 247,574 individuals who had at least one measurement of serum vitamin D in the period from April 2004 to January 2010. In the present study, the first measurement of vitamin D from each individual from the CopD database was linked at individual-level to The Danish Cancer Registry¹¹, The National Patient Registry¹², and the Danish Civil Registration System¹³; with date of last follow-up as of December 31st 2014. We only included the first measurement to exclude bias by possible supplementation initiated after the first measurement. Firstly, we excluded individuals with replacement social security numbers since they

are temporary until a valid social security number is provided (N = 716). Then, individuals with a pre-existing cancer diagnosis from the Danish Cancer Registry (N = 26,644) at the time of the first vitamin D measurement were excluded. Thereafter, remaining individuals who had a cancer diagnosis in the National Patient Registry (N = 2970) at the time of the first vitamin D measurement were excluded to reach a final cohort size of 217,244 individuals.

Analysis of vitamin D

Vitamin D levels were assessed in serum using two different commercially available assays: LIAISON 25(OH)D assay (Diasorin, Italy); and OCEIA 25(OH)D3 and 25(OH)D2 (Immunodiagnostic Systems, UK) quantifying both 25-hydroxy vitamin D₂ and 25-hydroxy vitamin D₃ as described in detail by Durup *et al.*⁸. Quantitative values less than 10 nmol/L were set to 10 nmol/L due to the lower limit of the assays.

Confounding variables

Besides age, sex and month of sampling, comorbidity was assessed by the Charlson Comorbidity Index^{14,15} using the International Classification of Diseases (ICD-10) codes. The Charlson Comorbidity Index was included at time of vitamin D analysis with all available diagnoses registered in the National Patient Registry since 1977.

Study endpoints

Information about incident cancers was obtained from The Danish Cancer Registry based on ICD-10 codes and grouped as shown in Supporting Information Table S1. Non-Hodgkin lymphoma was examined as a subgroup of hematological cancers as well as included in the hematological cancers. Each type of cancer with number of events above 200 in the follow-up period was included as outcome variables. Information on emigration and vital status was obtained from the Danish Civil Registration System with the date of last follow-up being December 31st 2014.

Statistical analysis

The association between vitamin D levels and the incidence of each type of cancer was estimated using a Cox proportional hazards model with time since first vitamin D measurement as the underlying timescale. All subjects were followed to the time of first cancer (any cancer diagnosis, N = 18,359), time of emigration (N = 5583), time of death (N = 24,087), or end of follow-up (by December 31st 2014), whichever came first.

The associations were presented as hazard ratios (HRs) with corresponding 95% confidence interval (CI) from crude models as well as from models adjusted for potential confounding effects from comorbidity as the Charlson Comorbidity Index, age at blood sampling in one-year intervals, sex, and month of blood sampling. All potential confounder variables were included as strata variables to allow for different underlying hazards in the strata.

The assumption of proportional hazards for the vitamin D variable in the Cox regression analysis was checked graphically using Schoenfeld residual plots. To exclude prevalent cases, we also computed the effects with delayed entry of one year as well as 5 years. Furthermore, we performed sensitivity analyses for sex specific effects and analyses with vitamin D levels at the lower limit of the assay of 10 nmol/L set to 5 nmol/L. Also, we analyzed individuals with blood samplings from April 2005 and onwards to exclude bias from measurements performed from April 2004 to April 2005 that were not the first measurement of vitamin D in the individual.

To detect non-linear associations between vitamin D levels and the incidence of cancer, we fitted associations of vitamin D levels and incidence of cancer for each cancer type using restricted cubic splines with 4 knots placed at 12.5, 25, 75, and 100 nmol/L vitamin D, using 50 nmol/L as the reference. The lower knots were derived from the cut-offs used in clinical practice in Europe¹⁶. Graphical presentations of estimates together with 95% pointwise CI for all cancer types were reviewed but only those that had significant findings by Cox regression analysis were displayed as figures. Since the study was register based there were no missing data or loss to follow-up.

The statistical analyses were performed in the SAS 9.3 software (SAS institute, Cary, USA). Descriptive analyses of quantitative variables were reported as medians with interquartile ranges (IQR), and the categorical variables as numbers and percentages of total (%). All HRs were computed with 95% CI. P-values were two-sided and considered statistically significant if less than 0.05.

Results

The study population of 217,244 individuals had a median level of vitamin D of 46 nmol/L (IQR 27–67 nmol/L), a median age of 48.8 years (IQR 33.5–64.1 years), female predominance (65.3%), and a low comorbidity burden (Charlson Comorbidity Index of 0 in 79.5%) with pulmonary disease being the most frequent comorbidity. Vitamin D levels were grouped by clinical cut-offs into severe deficiency (<12.5 nmol/L), moderate deficiency (12.5–25 nmol/L), insufficiency (25–50 nmol/L), sufficiency (50–75 nmol/L), moderately high levels (75–100 nmol/L), high levels (100–125 nmol/L), and very high levels (≥ 125 nmol/L) for tabulation of baseline characteristics by the level of vitamin D (Table 1).

A total of 18,359 individuals were diagnosed with an incident cancer (8.5% of the population) during the follow-up period. Non-melanoma skin cancer (N = 5045) was the most

frequent incident cancer followed by breast cancer (N = 2167), lung cancer (N = 1707), prostate cancer (N = 1470), and colon-rectosigmoidal cancers (N = 1108). The median level of vitamin D differed depending on cancer type ranging from 47 nmol/L in individuals developing an incident lung or rectum cancer to 58 nmol/L in individuals developing a non-melanoma skin cancer (Table 2).

In the unadjusted Cox regression analysis, increments of 10 nmol/L in the level of vitamin D were significantly positively associated with almost all incident cancer types (Table 2). However, when adjusting for the potential confounding variables, no associations were found for breast-, urinary-, colon-rectosigmoidal-, rectum-, ovary, corpus uteri or cancers of the central nervous system. However, non-melanoma (HR 1.09 [1.09–1.1]) and melanoma skin cancer (HR 1.1 [1.08–1.13]), as well as prostate (HR 1.05 [1.03–1.07]) and hematological cancers (HR 1.03 [1.01–1.06]) retained a significant positive association with vitamin D levels, while lung cancer showed a negative association (HR 0.95 [0.93–0.97]) (Table 2). Applying delayed entry of one year or five years produced similar results (Fig. 1, Table 3). For melanoma skin cancer, the hazard ratio seemed to peak around a vitamin D level of 80 nmol/L (Fig. 2a) while it further increased for non-melanoma skin cancer (Fig. 2b). For individuals with an incident prostate cancer, the rate of increase in hazard ratio was largest below a vitamin D level of 80 nmol/L (Fig. 3a) in contrast to individuals with incident hematological cancers or incident non-Hodgkin lymphomas where the largest rate of increase in hazard ratio was seen at the level above 80 nmol/L and 100 nmol/L, respectively (Figs. 3b and 3c). Finally, for individuals with an incident lung cancer, the strongest association was for vitamin D levels below 30 nmol/L (Fig. 3c). The sensitivity analyses yielded no differences when examining the effect of sex, except for non-Hodgkin lymphoma, where the association was only significant in women (Table S2); when only examining individuals who had their blood analyzed for vitamin D from April 2005 and onwards (Table S3–4); nor when calculating with the lower limit of vitamin D set to 5 nmol/L (data not shown).

Discussion

We examined associations between the level of vitamin D and the incidence of several cancer types in a large population from general practice in Denmark. We found that the level of vitamin D showed no association with most cancer types, while in some cancer types, higher levels of vitamin D were associated with both higher and lower incidence of cancer depending on the type of cancer examined.

The CopD study was observational and thus we could not examine causality due to possible residual confounding and reverse causation. Furthermore, a general problem of observational cohort studies is that participants tend to be healthier than their source population. The opposite could be an issue for the present study since the request for vitamin D analysis,

Table 1. Baseline characteristics by the level of 25-hydroxy vitamin D

	25-hydroxy vitamin D (nmol/L)							
	all	<12.5	12.5–25	25–50	50–75	75–100	100–125	≥125
N	217,244	12,268 (5.6%)	36,770 (16.9%)	71,762 (33.0%)	58,073 (26.7%)	26,109 (12.0%)	8,175 (3.8%)	4,087 (1.9%)
Age	48.8 (33.5–64.1)	43.0 (30.5–58.7)	44.3 (31.5–59.8)	48.9 (33.9–63.6)	51.8 (35.5–66.0)	52.0 (34.1–66.3)	50.2 (31.9–65.8)	48.8 (30.7–64.8)
Male sex	78,414 (34.7%)	5,047 (41.1%)	14,553 (39.6%)	27,882 (38.9%)	19,710 (33.9%)	7,898 (30.2%)	2,274 (27.8%)	1,050 (25.7%)
Comorbidity								
Charlson Comorbidity Index of zero	172,735 (79.5%)	9,535 (77.7%)	28,922 (78.7%)	57,019 (79.5%)	46,619 (80.3%)	20,947 (80.2%)	6,423 (78.6%)	3,270 (80%)
Diabetes	16,944 (7.8%)	1,384 (11.3%)	3,789 (10.3%)	5,951 (8.3%)	3,747 (6.5%)	1,444 (5.5%)	423 (5.2%)	206 (5.0%)
Heart disease	20,918 (9.6%)	1,277 (10.4%)	3,622 (9.9%)	6,942 (9.7%)	5,426 (9.3%)	2,431 (9.3%)	832 (10.2%)	388 (9.5%)
Pulmonary disease	24,180 (11.1%)	1,584 (12.9%)	4,414 (12.0%)	7,922 (11.0%)	6,055 (10.4%)	2,764 (10.6%)	947 (11.6%)	494 (12.1%)
Neurological disease and dementia	23,460 (10.8%)	1,326 (10.8%)	3,841 (10.5%)	7,652 (10.7%)	6,218 (10.7%)	2,890 (11.1%)	1,027 (12.6%)	506 (12.4%)
Liver disease	5,080 (2.3%)	492 (4.0%)	1,150 (3.1%)	1,664 (2.3%)	1,061 (1.8%)	462 (1.8%)	157 (1.9%)	94 (2.3%)
Renal disease	3,272 (1.5%)	217 (1.8%)	628 (1.7%)	1,039 (1.5%)	842 (1.5%)	360 (1.4%)	124 (1.5%)	63 (1.5%)
Ulcer	7,337 (3.4%)	592 (4.8%)	1,433 (3.9%)	2,474 (3.5%)	1,704 (2.9%)	728 (2.8%)	263 (3.2%)	143 (3.5%)
Rheumatological disease	5,404 (2.5%)	181 (1.5%)	688 (1.9%)	1,574 (2.2%)	1,569 (2.7%)	870 (3.3%)	331 (4.1%)	191 (4.7%)
HIV	119 (0.1%)	5 (0.0%)	25 (0.1%)	38 (0.1%)	30 (0.1%)	15 (0.1%)	5 (0.1%)	<5 (0.0%)

Age is shown as median with inter quartile ranges (IQR). All other variables are shown as numbers and percentages (%).

Table 2. Results from cox regression analysis

Cancer	Cases N	25-hydroxy vitaminD, nmol/L Median (IQR)	Unadjusted			Adjusted ¹		
			HR	95% CI	p	HR	95% CI	p
Non-melanoma skin cancer	5,045	58 (40–78)	1.11	1.10–1.12	<0.0001	1.09	1.09–1.10	<0.0001
Breast	2,167	51 (33–70)	1.05	1.03–1.06	<0.0001	1.00	0.99–1.02	0.6
Lung	1,707	47 (28–66)	1.00	0.98–1.01	0.8	0.95	0.93–0.97	<0.0001
Prostate	1,470	51 (35–70)	1.05	1.03–1.07	<0.0001	1.05	1.03–1.07	<0.0001
Colon-rectosigmoidal	1,108	49 (32–69)	1.03	1.01–1.05	0.0004	0.98	0.96–1.00	0.1
Urinary	1,016	48 (30–66)	1.02	1.00–1.04	0.2	0.99	0.96–1.01	0.3
Hematological	968	53 (32–74)	1.06	1.04–1.08	<0.0001	1.03	1.01–1.06	0.004
Non-Hodgkin lymphoma	425	53 (31–73)	1.03	0.99–1.06	0.1	1.03	1.00–1.07	0.07
Central nervous system	689	49 (31–69)	1.03	1.00–1.05	0.03	1.00	0.98–1.03	0.8
Melanoma of the skin	684	57 (41–75)	1.10	1.08–1.13	<0.0001	1.10	1.08–1.13	<0.0001
Rectum	461	47 (32–67)	1.01	0.98–1.04	0.6	0.98	0.94–1.01	0.2
Corpus-uteri	347	52 (33–69)	1.04	1.01–1.08	0.01	0.99	0.96–1.03	0.7
Ovary, fallopian tube and broad ligament	254	52 (34–69)	1.05	1.01–1.09	0.01	0.99	0.94–1.03	0.6

Abbreviations: IQR, Interquartile range; CI, confidence intervals. Incident cancers, 25-hydroxy vitamin D levels, and hazard ratios (HR) from both unadjusted and adjusted cox regression analysis per 10 nmol/L increments in 25-hydroxy vitamin D.

¹Adjusted for age in 1-year intervals, sex, month of sampling, and comorbidity.

and thereby the study participants, was selected by general practitioners. The generalizability to the entire population may therefore be a concern. However, in 2010 the background population serviced by the Copenhagen General Practitioners Laboratory was comprised of approximately 1.1 million people and almost one quarter thereof had vitamin D assessed in the period from 2004 to 2010, enhancing the likelihood of generalizability of our study. The cancer incidence of the CopD study population was higher than expected. We observed 18,359 incident cancer diagnoses, whereas an age-

and sex-standardized calculation based on the cancer incidence rates for the period 2004 to 2014 in the entire Danish population revealed an expected number of 11,733 (5.4%). The major difference was seen for non-melanoma skin cancer with 5045 cancers observed vs. 643 expected. This was even more clear if calculated with delayed entry of 5 years where there was a total of 3664 observed cancers vs. 2698 expected and the numbers for non-melanoma skin cancer were 1062 observed cancers vs. 145 expected. This points to, that the CopD population may be more closely followed in the health




Figure 1. Forest plot showing association with cancer incidence per 10 nmol/L increments of 25-hydroxy vitamin D. Hazard ratios (HR) are presented with 95% confidence intervals (CI). Analyses are performed with delayed entry of 1 year.

Table 3. Results from analyses performed with delayed entry of 5 years

Delayed entry 5 years	N	HR	95% CI	p
Non-melanoma skin cancer	1,062	1.11	1.09–1.13	<0.0001
Breast	455	1.02	0.99–1.05	0.2
Lung	318	0.93	0.89–0.98	0.003
Prostate	221	1.09	1.04–1.15	0.0002
Colon-rectosigmoidal	222	0.97	0.93–1.03	0.3
Urinary	213	0.98	0.93–1.04	0.5
Hematological	181	1.08	1.03–1.13	0.002
Non-Hodgkin lymphoma	84	1.10	1.03–1.17	0.006
Central nervous system	144	1.00	0.95–1.06	0.9
Melanoma of the skin	130	1.14	1.08–1.20	<0.0001
Rectum	88	0.98	0.91–1.06	0.7
Corpus-uteri	90	0.99	0.92–1.06	0.7
Ovary, fallopian tube and broad ligament	53	0.98	0.89–1.08	0.7

Abbreviation: CI, confidence intervals. Incident cancers, 25-hydroxy vitamin D levels, and hazard ratios (HR) from adjusted¹ cox regression analysis per 10 nmol/L increments in 25-hydroxy vitamin D.

¹Adjusted for age in 1 year intervals, sex, month of sampling, and comorbidity.

system compared to the general population. Another concern is the skewed sex distribution with an overweight of women, especially in the groups with high levels of vitamin D, reflecting the well-known higher frequency of health concern in women. This could be the reason for the higher numbers of non-Hodgkin lymphomas in women found in our study compared to what is seen in the general population where these diseases have male predominance. As revealed in the sensitivity analysis, the association of non-Hodgkin lymphoma with vitamin D was only significant in women. However, the associations in men and women were not significantly different by interaction analysis.

Since the study was register based, we had complete follow-up but no available information on smoking habits, alcohol consumption, obesity or exercise. Confounding by these factors can therefore neither be evaluated nor ruled out. Inclusion of the Charlson Comorbidity Index¹⁴ was done to account for diseases that arise from these exposures. Outcomes (cancer incidence,

emigrations, and overall mortality) were obtained by registry linkage. The Danish Cancer Registry and The Danish Civil Registration system both have very high validity, and the risk of misclassification is considered minimal. Misclassification could be of greater concern as to the vitamin D exposure assessment. We only included one sampling per participant and the assays used are known to have some variability. However, all measurements were performed at the same laboratory with well documented and internationally approved quality assured assays to reduce this variability⁸. The potential errors related to vitamin D assessment would most likely be non-differential and thereby lead to an underestimation of the associations.

Several other studies, both separate studies and meta-analyses, have examined the association between vitamin D and cancer incidence^{2,17}. Like the present study, Skaaby *et al.* showed a significantly higher incidence of non-melanoma skin cancers with higher levels of vitamin D in approximately 12,000 individuals pooled from 3 population based studies




Figure 2. Restricted cubic spline curves for incident skin cancers by the level of 25-hydroxy vitamin D. Hazard ratios (HR) are presented with 95% pointwise confidence intervals (CI). Analyses are performed with delayed entry of 1 year. (a) Melanoma. (b) Non-melanoma.




Figure 3. Restricted cubic spline curves for incident cancers by the level of 25-hydroxy vitamin D. Hazard ratios (HR) are presented with 95% pointwise confidence intervals (CI). Analyses are performed with delayed entry of 1 year. (a) Prostate cancer. (b) Hematological cancer. (c) Non-Hodgkin lymphoma. (d) Lung cancer.

carried out in Denmark from 1993 to 2008¹⁸. Thus, it is likely there is confounding by sun exposure for non-melanoma skin cancer as these cancers are induced by exposure of the skin to the ultraviolet light from the sun¹⁹. Furthermore, an inverse association of vitamin D levels with lung cancer was shown by Afzal *et al.* in more than 9000 individuals from The Copenhagen City Heart Study²⁰. Of note, their findings were unaffected by smoking habits.

For several cancer types, we did not find any association with the level of vitamin D, in contrast to other studies. For example, a recent meta-analysis performed in the elderly compiled from several population based cohorts in Europe showed an association of higher risk of breast cancer with higher vitamin D levels²¹. However, individuals in the CopD study cohort were younger, and therefore the results are not directly comparable. Also, a large case-control study based on pooling of 17 cohorts showed a protective effect of higher vitamin D levels with regards to the risk of colon-rectosigmoidal cancers in women²². We do not find incident colon-rectosigmoidal cancers to be associated with the level of vitamin D, neither in women only. In that respect confounding needs to be considered. Information on important lifestyle risk factors as smoking, obesity, unhealthy diet and physical inactivity were not available in the current study and confounding by these

factors are thereby possible. However, these factors are most often found related to lower blood levels of vitamin D^{23,24}. It is therefore more likely that adjustment for these factors would lead to the opposite finding in our study, i.e. that higher levels of vitamin D were associated with higher incidence of colon-rectosigmoidal cancers. Also, recent data from a randomized calcium and vitamin D supplementation trial suggested that supplementation increased the risk of subsequent serrated polyps of the colon, but as a late effect²⁵. We do not have information on the intake of calcium or vitamin D supplements in our study, but in Denmark, there is generally a high consumption of supplements in the Danish population (60% of females and 51% of males aged 18 to 75 years) with a relatively low median level of dietary intake of 7.8–8.4 μg for users of dietary supplements vs. 2.0–2.9 μg in non-users¹⁰. Furthermore, recent studies have examined vitamin D receptor polymorphisms and risk of colorectal diseases and found different results for different disease entities²⁶, and a large Mendelian randomization study provides no evidence for a causal relationship between vitamin D and risk of colorectal cancers, although small effect sizes and non-linear relationships cannot be ruled out²⁷. Like our study, none of these studies had information on potential confounding factors such as smoking habits, alcohol consumption, body

fatness, physical activity or family history of cancer. Thus, the possible association between vitamin D levels and colorectal cancers warrants further large studies including information on potential confounders and genetic susceptibility as well as more specific disease entities as outcome.

For prostate cancer, Schenk *et al* showed no association of vitamin D levels with total prostate cancer risk in a nested case control study of 1700 cases and controls from the Prostate Cancer Prevention Trial²⁸. However, when accounting for Gleason score, there was a modest increase in the risk of prostate cancer with a Gleason score of 2–6, with increasing vitamin D levels, but a decrease in risk of prostate cancer with a Gleason score 8–10. Thus, our results could be biased by a predominance of low Gleason score groups identified through screening using Prostate Specific Antigen. In Denmark, the incidence of prostate cancer rose by 2.5-fold in the late 1990's, largely due to an increase in the diagnosis of locally advanced prostate cancers²⁹. In parallel to our results, a large Norwegian population based nested case control study showed a positive association between a 30 nmol/L increase in the vitamin D level and the risk of prostate cancer, not depending on the stage of the disease at diagnosis³⁰. However, staging was not done by Gleason score in their study.

The positive association between higher vitamin D levels and the incidence of non-Hodgkin lymphomas is corroborated by a recent meta-analysis in finding no protective effect of higher vitamin D levels in relation to the risk of developing non-Hodgkin lymphoma³¹. Several cancers are associated with immune suppression, and non-Hodgkin lymphomas occur more often in patients with non-melanoma skin cancer³². This mutual association with immune suppression could explain that we find both types of cancers to be positively associated with the level of vitamin D.

For both skin cancers as well as for prostate and hematological cancers, and especially non-Hodgkin lymphomas we found that higher levels of vitamin D were associated with

higher incidence, while we found an inverse association with lung cancer. The active metabolite of vitamin D, calcitriol, has several effects on both cancer cells and immune cells and can also mediate the effects of tobacco carcinogens⁶. Moreover, UV-radiation can affect CD4+ T-cells toward a more immune suppressive environment³³. Thus, it is possible that the blood level of vitamin D could be related to the evolution and progression of cancer. However, it is also likely that vitamin D is a surrogate marker for the function of the immune system at the individual level. This might explain why studies conducted in cohorts from countries at different latitudes find differences in 'optimal' levels of vitamin D such as studies conducted in the USA vs. in countries from northern Europe³⁴. These hypotheses remain to be tested.

To conclude, vitamin D levels are not associated with the incidence of several major cancers such as breast, urinary, and colon-rectosigmoidal cancers in a population from primary care in Denmark, but higher vitamin D levels are associated with a higher incidence of skin, prostate, hematological cancers, and non-Hodgkin lymphomas solely as well as a lower incidence of lung cancer. These results should be interpreted in the light of the representativeness of the cohort as well as the known limitation of registry studies in lack of information on potential confounding factors. Our study results do not support an overall protective effect against cancer by vitamin D.

Acknowledgements

The authors would like to acknowledge Nick Martinussen for data management and preparation of figures. The funders had no influence on study design or interpretation of the results.

Data availability statement

The data from our study are deposited at Statistics Denmark (ref no 706282) and can only be accessed with a secure access granted by Statistics Denmark.

References

1. Feldman D, Krishnan AV, Swami S, et al. The role of vitamin D in reducing cancer risk and progression. *Nat Rev Cancer* 2014;14:342–57.
2. Mondul AM, Weinstein SJ, Layne TM, et al. Vitamin D and cancer risk and mortality: state of the science, gaps, and challenges. *Epidemiol Rev* 2017;39:28–48.
3. Gandini S, Boniol M, Haukka J, et al. Meta-analysis of observational studies of serum 25-hydroxyvitamin D levels and colorectal, breast and prostate cancer and colorectal adenoma. *Int J Cancer* 2011;128:1414–24.
4. Xu Y, Shao X, Yao Y, et al. Positive association between circulating 25-hydroxyvitamin D levels and prostate cancer risk: new findings from an updated meta-analysis. *J Cancer Res Clin Oncol* 2014;140:1465–77.
5. Colotta F, Jansson B, Bonelli F. Modulation of inflammatory and immune responses by vitamin D. *J Autoimmun* 2017;85:78–97.
6. Zhang R, Zhao H, Dong H, et al. 1 α ,25-dihydroxyvitamin D(3) counteracts the effects of cigarette smoke in airway epithelial cells. *Cell Immunol* 2015;295:137–43.
7. WHO, Vitamin D and Cancer IARC, 2008. 5.
8. Durup D, Jorgensen HL, Christensen J, et al. A reverse J-shaped association of all-cause mortality with serum 25-hydroxyvitamin D in general practice: the CopD study. *J Clin Endocrinol Metab* 2012;97:2644–52.
9. Sempos CT, Durazo-Arvizu RA, Dawson-Hughes B, et al. Is there a reverse J-shaped association between 25-hydroxyvitamin D and all-cause mortality? Results from the U.S. nationally representative NHANES. *J Clin Endocrinol Metab* 2013;98:3001–9.
10. Tetens I, Biloft-Jensen A, Spagner C, et al. Intake of micronutrients among Danish adult users and non-users of dietary supplements. *Food Nutr Res* 2011;55:7153.
11. Gjerstorff ML. The Danish cancer registry. *Scand J Public Health* 2011;39(7 Suppl):42–5.
12. Schmidt M, Schmidt SA, Sandegaard JL, et al. The Danish National Patient Registry: a review of content, data quality, and research potential. *Clin Epidemiol* 2015;7:449–90.
13. Pedersen CB. The Danish civil registration system. *Scand J Public Health* 2011;39(7 Suppl):22–5.
14. Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. *J Chronic Dis* 1987;40:373–83.
15. Quan H, Sundararajan V, Halfon P, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. *Med Care* 2005;43:1130–9.
16. Bischoff-Ferrari HA, Giovannucci E, Willett WC, et al. Estimation of optimal serum concentrations of 25-hydroxyvitamin D for multiple health outcomes. *Am J Clin Nutr* 2006;84:18–28.

17. Lappe J, Watson P, Travers-Gustafson D, et al. Effect of vitamin D and calcium supplementation on cancer incidence in older women: a randomized clinical trial. *JAMA* 2017;317:1234–43.
18. Skaaby T, Husemoen LL, Thuesen BH, et al. Prospective population-based study of the association between serum 25-hydroxyvitamin-D levels and the incidence of specific types of cancer. *Cancer Epidemiol Biomarkers Prev* 2014;23:1220–9.
19. Mohania D, Chandel S, Kumar P, et al. Ultraviolet radiations: skin defense-damage mechanism. *Adv Exp Med Biol* 2017;996:71–87.
20. Afzal S, Bojesen SE, Nordestgaard BG. Low plasma 25-hydroxyvitamin D and risk of tobacco-related cancer. *Clin Chem* 2013;59:771–80.
21. Ordonez-Mena JM, Schottker B, Fedirko V, et al. Pre-diagnostic vitamin D concentrations and cancer risks in older individuals: an analysis of cohorts participating in the CHANCES consortium. *Eur J Epidemiol* 2016;31:311–23.
22. McCullough ML, Zoltick ES, Weinstein SJ, et al. Circulating vitamin D and colorectal cancer risk: an international pooling project of 17 cohorts. *J Natl Cancer Inst* 2018. <https://doi.org/10.1093/jnci/djy087>. [Epub ahead of print]
23. Jiang CQ, Chan YH, Xu L, et al. Smoking and serum vitamin D in older Chinese people: cross-sectional analysis based on the Guangzhou biobank cohort study. *BMJ Open* 2016;6:e010946.
24. Parva NR, Tadepalli S, Singh P, et al. Prevalence of vitamin D deficiency and associated risk factors in the US population (2011–2012). *Cureus* 2018;10:e2741.
25. Crockett SD, Barry EL, Mott LA, et al. Calcium and vitamin D supplementation and increased risk of serrated polyps: results from a randomised clinical trial. *Gut* 2018;gutjnl-2017-315242. <https://doi.org/10.1136/gutjnl-2017-315242>. [Epub ahead of print]
26. Cho YA, Lee J, Oh JH, et al. Vitamin D receptor FokI polymorphism and the risks of colorectal cancer, inflammatory bowel disease, and colorectal adenoma. *Sci Rep* 2018;8:12899.
27. He Y, Timofeeva M, Farrington SM, et al. Exploring causality in the association between circulating 25-hydroxyvitamin D and colorectal cancer risk: a large Mendelian randomisation study. *BMC Med* 2018;16:142.
28. Schenk JM, Till CA, Tangen CM, et al. Serum 25-hydroxyvitamin D concentrations and risk of prostate cancer: results from the prostate cancer prevention trial. *Cancer Epidemiol Biomarkers Prev* 2014;23:1484–93.
29. Outzen M, Brasso K, Martinussen N, et al. Prostate cancer in Denmark 1978–2009—trends in incidence and mortality. *Acta Oncol* 2013;52:831–6.
30. Meyer HE, Robsahm TE, Bjorge T, et al. Vitamin D, season, and risk of prostate cancer: a nested case-control study within Norwegian health studies. *Am J Clin Nutr* 2013;97:147–54.
31. Lu D, Chen J, Jin J. Vitamin D status and risk of non-Hodgkin lymphoma: a meta-analysis. *Cancer Causes Control* 2014;25:1553–63.
32. Engels EA, Parsons R, Besson C, et al. Comprehensive evaluation of medical conditions associated with risk of non-Hodgkin lymphoma using Medicare claims ("MedWAS"). *Cancer Epidemiol Biomarkers Prev* 2016;25:1105–13.
33. Gorman S, Kuritzky LA, Judge MA, et al. Topically applied 1,25-dihydroxyvitamin D3 enhances the suppressive activity of CD4+CD25+ cells in the draining lymph nodes. *J Immunol* 2007;179:6273–83.
34. Grant WB, Karras SN, Bischoff-Ferrari HA, et al. Do studies reporting 'U'-shaped serum 25-hydroxyvitamin D-health outcome relationships reflect adverse effects? *Dermatoendocrinol* 2016;8:e1187349.